Mark Breckenridge
About Mark Breckenridge
Mark Breckenridge is the Clinical Development Lead for Product Design & Delivery in Oncology Clinical Development at Bristol Myers Squibb, with extensive experience in oncology clinical development and medical strategy.
Current Role at Bristol Myers Squibb
Mark Breckenridge is currently serving as the Clinical Development Lead, Product Design & Delivery, Oncology Clinical Development at Bristol Myers Squibb. In this role, he is involved in leading the clinical development initiatives focused on oncology, emphasizing product design and efficient delivery methods. His work is integral in bringing forward innovative cancer treatment options and ensuring rigorous clinical standards.
Previous Experience at AstraZeneca
Before his current role, Mark Breckenridge worked at AstraZeneca as the Senior Director, Global Development Scientist from 2020 to 2021. During his tenure, he played a significant role in the global development projects related to oncology treatments. His contributions were pivotal in advancing oncology therapeutics and ensuring their progress through various development stages.
Immuno-Oncology Focus at Bristol-Myers Squibb
From 2018 to 2020, Mark held the position of HQ (Global) Medical Director, Immuno-Oncology, Lung at Bristol-Myers Squibb. In this capacity, he focused specifically on immuno-oncology with a particular emphasis on lung cancer. His leadership in this area contributed to the strategic direction and clinical development of immuno-oncology therapies aimed at improving patient outcomes.
Educational Background
Mark Breckenridge's educational journey began at Columbia University, where he earned a BS in Biomedical Engineering from 1999 to 2003. He furthered his education at Case Western Reserve University, achieving a PhD in Biophysics and Bioengineering from 2003 to 2010. His academic background laid a robust foundation for his subsequent career in clinical development and medical strategy.
Commitment to Patient Safety
Mark Breckenridge shows a strong commitment to patient safety and public health in his professional roles. He works closely with patients' physicians to determine the best actions for pre-approval access to investigational medicines. Additionally, he manages risk evaluation and mitigation strategies (REMS) effectively, ensuring patient safety across various treatment programs. His dedication is evident through the administration of legacy Celgene REMS programs that emphasize safe usage.